GOALI: Catalytic Stereoselective Cross-Coupling Reactions

目标：催化立体选择性交叉偶联反应

• 批准号: 2246869
• 负责人: James Morken
• 金额: $ 57.5万
• 依托单位: Boston College
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2026-05-31
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2246869&HistoricalAwards=false
• 关键词: GOALI; Catalytic; Stereoselective; Cross; Coupling

With the support of the Chemical Catalysis Program in the Division of Chemistry, Professor James Morken of Boston College and Dr. Robert Singer of Pfizer are studying the development of new chemical reactions that produce molecules having a well-defined three-dimensional topology. Because a significant fraction of molecules having a defined three-dimensional shape are present in newly approved drugs (44% of new pharmaceuticals in 2015), chemical reactions that can control this sp3-rich topology are valuable to the pharmaceutical and chemical industries. The goal of this research is to develop such reactions with the expectation that these processes will streamline drug-development and improve access to important medicines. This academic-industrial partnership is studying new palladium and copper-based reactions for their ability to act as effective catalysts to control the three dimensional topology of the product. They are also evaluating whether these catalysts can operate efficiently, economically, and with minimal production of hazardous waste. By being part of the collaboration through the GOALI (grant opportunities for academic liaison with industry) award, the undergraduate and graduate students involved in the research will acquire training that is critical to science-based careers in fields ranging from medicine to pharmaceuticals, and to chemistry. Under this GOALI award, the Morken research group at Boston College and collaborators led by Dr. Robert Singer at Pfizer are developing enantioselective cross-coupling reactions that operate on meso-diborylalkane substrates. Chiral catalysts are being developed that can affect cross-coupling reactions that selectively break the symmetry of the diboryl reactant and deliver products that retain one of the original boronic ester groups. In addition to the design of appropriate reactions and the examination of their synthetic utility, the team is developing concise routes to new chiral phosphine ligands that are expected to not only be useful in the the diborylalkane reactions but also in other catalytic transformations. Additionally, mechanistic experiments are being carried out to determine why diboryl substrates are unusually reactive in cross-coupling reactions and whether the gained information can be used in the design of new reactions.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

在化学系化学催化项目的支持下，波士顿学院的James Morken教授和辉瑞公司的Robert Singer博士正在研究新化学反应的发展，这些反应产生具有明确三维拓扑结构的分子。 由于新批准的药物（2015年占新药的44%）中存在相当大一部分具有明确三维形状的分子，因此可以控制这种富含sp3拓扑结构的化学反应对制药和化学工业很有价值。 这项研究的目标是开发这种反应，期望这些过程将简化药物开发并改善重要药物的获得。 该学术-工业合作伙伴关系正在研究新的钯和铜基反应，以确保它们能够作为有效的催化剂来控制产品的三维拓扑结构。 他们还在评估这些催化剂是否能够高效、经济地运行，并且最大限度地减少危险废物的产生。 通过GOALI（与工业界学术联络的赠款机会）奖的合作的一部分，参与研究的本科生和研究生将获得培训，这对从医学到制药和化学等领域的科学职业至关重要。 在这个GOALI奖项下，波士顿学院的Morken研究小组和辉瑞的Robert Singer博士领导的合作者正在开发对映选择性交叉偶联反应，该反应在meso-二硼基烷烃底物上进行。 正在开发的手性催化剂可以影响交叉偶联反应，选择性地打破二硼基反应物的对称性，并提供保留原始硼酸酯基团之一的产物。 除了设计适当的反应和检查它们的合成效用外，该团队正在开发新的手性膦配体的简洁路线，这些配体预计不仅可用于二硼基烷烃反应，而且可用于其他催化转化。 此外，还进行了机械实验，以确定为什么二硼基底物在交叉偶联反应中具有异常的反应性，以及所获得的信息是否可以用于设计新的反应。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。